Trial ID or NCT#

NCT00980460

Status

RECRUITING

Purpose

This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs (cancer fighting medicines), and when necessary, liver transplant, are the main current treatments for hepatoblastoma. The stage of the cancer is one factor used to decide the best treatment. Treating patients according to the risk group they are in may help get rid of the cancer, keep it from coming back, and decrease the side effects of chemotherapy.

Official Title

Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment

Eligibility Criteria

Ages Eligible for Study: Younger than 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Sheri L. Spunt, MD, MBA
Pediatric oncologist, Sarcoma specialist
Endowed Professor of Pediatric Cancer
Neyssa Marina

Contact us to find out if this trial is right for you.

CONTACT

Christina Baggott
(650) 497-7659